Daré Bioscience

Daré Bioscience

Pharmaceuticals
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women’s health.

$13.9M

Market Cap • 9/11/2026

2005

(21 years)

Founded

2014

(12 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

P/S

10,2

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

EPS

Market Cap

Market Cap

13,9M

EV

2,3M

EV/Revenue

1,7

EV/EBITDA

-0,3

EV/EBIT

-0,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-146,2%

Total Yield

-146,2%

Payout

0%

Retained Earnings

-194,7M

Profitability

Gross Margin

37,2%

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

197,6%

Capex/Revenue

33,8%

Capex/D&A

21,7%

Capex/OCF

-4,1%

SBC/OCF

% PPE

14%

% Goodwill

0%

ROE

165,3%

ROIC

Growth

CAGR Op. Income 5Y

-19,5%

CAGR Net Income 5Y

-19,5%

CAGR EPS 5Y

-40,6%

CAGR OCF 5Y

-20,1%

Leverage

N.D./EBITDA

1,3

Debt/Equity

0%

Current Ratio

1

Quick Ratio

0,8

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium